Fineline Cube

Follow:
14486 Articles
Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC
CompanyDrug

Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC

Ab&B Bio‑Tech Wins NMPA Approval for First‑Ever Quadrivalent Influenza Subunit Vaccine
CompanyDrug

Ab&B Bio‑Tech Wins NMPA Approval for First‑Ever Quadrivalent Influenza Subunit Vaccine

Sanofi’s Tzield Earns China NMPA Approval for Stage 2 Type 1 Diabetes
CompanyDrug

Sanofi’s Tzield Earns China NMPA Approval for Stage 2 Type 1 Diabetes

Zenas Secures $300 M Royalty Deal for Obexelimab – Royalty Pharma to Invest
CompanyDeals

Zenas Secures $300 M Royalty Deal for Obexelimab – Royalty Pharma to Invest

Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration
CompanyDeals

Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration

Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment
CompanyDeals

Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment

JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention
CompanyDrug

JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention

Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults
CompanyDrug

Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults

NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs
Policy / Regulatory

NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors
CompanyDrug

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide
CompanyDrug

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule
CompanyDeals

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule